AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.hindustantimes.com — the content belongs to Hindustan Times - World.